First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study

被引：3
|
作者：
Mok, Tony [1 ]
Schmid, Peter [2 ]
De Castro, Gilberto, Jr. [3 ]
Syrigos, Kostas [4 ]
Martin, Claudio [5 ]
Yamamoto, Nobuyuki [6 ]
Aren, Osvaldo [7 ]
Arrieta, Oscar [8 ]
Gottfried, Maya [9 ]
Jazieh, Abdul Rahman [10 ]
Ramlau, Rodryg [11 ]
Timcheva, Constanta [12 ]
Trani, Leonardo [13 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
[2] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[3] Fac Med Usp, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[4] Univ Athens, Athens, Greece
[5] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina
[6] Wakayama Med Univ, Dept Expt Therapeut Internal Med Resp Med & Med O, Wakayama, Japan
[7] Ciec Ctr Int Estudios Clin, Dept Oncol, Santiago, Chile
[8] Inst Nacl Cancerol Incan, Thorac Oncol Unit, Mexico City, DF, Mexico
[9] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel
[10] King Saud Univ Hlth Sci Natl Guards Hlth Affairs, Dept Oncol, Riyadh, Saudi Arabia
[11] Poznan Univ Med Sci, Dept Oncol, Poznan, Poland
[12] Mhat Womens Hlth, Med Oncol Clin, Sofia, Bulgaria
[13] Astrazeneca, Royston, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
MEDI4736; tremelimumab; durvalumab; Checkpoint blockade;
D O I：
10.1016/j.jtho.2016.11.1515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-022
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 50 条
  • [31] Platinum Doublet plus Durvalumab plus /- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226
    Juergens, R.
    Ellis, P.
    Tu, D.
    Hao, D.
    Laurie, S.
    Mates, M.
    Goss, G.
    Goffin, J.
    Bradbury, P.
    Tehfe, M.
    Kollmansberger, C.
    Brown-Walker, P.
    Smoragiewicz, M.
    Tsao, M.
    Seymour, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S291 - S292
  • [32] ARCTIC: Durvalumab plus tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
    Kowalski, D. M.
    Reinmuth, N.
    Orlov, S. V.
    Fischer, J. R.
    Sugawara, S.
    Mandziuk, S.
    Medine, D. M.
    Novello, S.
    Takeda, Y.
    Soo, R. A.
    Park, K.
    McCleod, M.
    Geater, S. L.
    Powell, M.
    May, R.
    Stockman, P.
    Planchard, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study
    Han, B.
    Chu, T.
    Yu, Z.
    Wang, J.
    Zhao, Y.
    Mu, X.
    Yu, X.
    Shi, X.
    Shi, Q.
    Guan, M.
    Ding, C.
    Geng, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1423 - S1424
  • [34] MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC
    Mamdani, H.
    Kim, S.
    Gentzler, R.
    Furqan, M.
    Shields, M. D.
    Jalal, S. I.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S207 - S207
  • [35] PROSPECTIVE OBSERVATIONAL COHORT STUDY OF SECOND-LINE CHEMOTHERAPY ADMINISTRATION AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NSCLC IN JAPAN (SAPPHIRE STUDY)
    Goto, Yasushi
    Yoh, Kiyotaka
    Kishi, Kazuma
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S869 - S870
  • [36] Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China
    Wang, F.
    Yang, H.
    Chen, H.
    Liu, M.
    Jiang, G.
    Yang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S631 - S632
  • [37] Prospective observational cohort study of second-line chemotherapy administration after first-line platinum-based chemotherapy for patients with advanced NSCLC in Japan (SAPPHIRE study)
    Yoh, Kiyotaka
    Goto, Yasushi
    Naito, Yoichi
    Kishi, Kazuma
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).
    Galsky, Matt D.
    Necchi, Andrea
    Sridhar, Srikala S.
    Ogawa, Osamu
    Angra, Natasha
    Hois, Stephan
    Xiao Feng
    Goluboff, Erik
    Bellmunt, Joquim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [39] Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
    Minato, Akinori
    Ohno, Daichi
    Murooka, Kazuki
    Okumura, Yutaka
    Takaba, Tomohisa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Harada, Kenichi
    Fujimoto, Naohiro
    IN VIVO, 2024, 38 (04): : 1927 - 1934
  • [40] Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
    Janne, P.
    Planchard, D.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S. -W.
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdivieso, N.
    Ahmed, S.
    Maurel, J. -M.
    Andrasina, I.
    Goldman, J.
    Ghiorghiu, D.
    Kulkarni, D.
    Huang, X.
    Kobayashi, K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S36 - S37
12345